News • Diagnostic

Potential therapeutic target for lung cancer

Scientists reported the key role of histone acetylation-regulated long noncoding RNA termed as lysosome cell death regulator (LCDR) in tumor survival, providing a potential diagnostic and therapeutic target for lung cancer.

Photo
Proposed model for the LCDR/hnRNP K/LAPTM5 axis promoting the pathogenesis of lung cancer
Source: GAO Shan

Led by Prof. GAO Shan from the Suzhou Institute of Biomedical Engineering and Technology of the Chinese Academy of Sciences (CAS), these scientists revealed that knockdown of the LCDR in lung cancer cells could promote apoptosis. Results were published in PNAS.

Lysosome is involved in cellular homeostasis and its dysregulation has been linked to various human diseases, including cancer. LncRNAs are noncoding RNAs with lengths longer than 200 nucleotides, whose dysregulation is associated with cancer hallmarks. They drive cancer growth and survival by interacting with DNA, RNA, and protein assemblies, including the heterogeneous ribonucleic acid protein (hnRNP) family, which functions as alternative splicing, RNA stability, and translation etc.

However, whether lncRNAs and/or hnRNPs are involved in lysosome-mediated cancer survival has not been elucidated.

In this study, LCDR binds to heterogeneous nuclear ribonucleoprotein K (hnRNP K) to regulate the stability of lysosomal-associated protein transmembrane 5 (LAPTM5) transcript that maintains the integrity of the lysosomal membrane.

According to the researchers, knockdown of LCDR, hnRNP K or LAPTM5 promoted lysosomal membrane permeabilization and lysosomal cell death, thus resulting in apoptosis. LAPTM5 overexpression or cathepsin B inhibitor partially restored the effects of this axis on lysosomal cell death in vitro and in vivo.

Similarly, targeting LCDR significantly decreased tumor growth of patient-derived xenografts of lung adenocarcinoma (LUAD) and led to significant cell death using nanoparticles (NPs)-mediated systematic siRNA delivery.

Moreover, LCDR/hnRNP K/LAPTM5 were upregulated in LUAD tissues, and their co-expression showed increased diagnostic value for LUAD.

These findings shed light on LCDR/hnRNP K/LAPTM5 as potential therapeutic targets and lysosome targeting is a promising strategy in cancer treatment.

Source: Chinese Academy of Sciences Headquarters

21.01.2022

Read all latest stories

Related articles

Photo

News • Elusive variants

Rare genetic markers of drug-resistant tuberculosis identified

The search for rare mutations in bacterial genome could lead to better diagnostics and treatments – reducing morbidity caused by the deadly disease.

Photo

News • Computational disease models

Digital twins aid patient treatment

Researchers have developed advanced computer models, or “digital twins”, of diseases, with the goal of improving diagnosis and treatment.

Photo

Report • Extended reality

The application of XR in mental health care

Mental disorders are among the leading causes of ill-health and disability worldwide, and the demand for a viable solution to battle the mental health crisis has risen. The past two decades have…

Related products

Hologic – SuperSonic Mach 30

Ultrasound

Hologic – SuperSonic Mach 30

Hologic, Inc.
Image Information Systems – iQ-View

Reading

Image Information Systems – iQ-View

IMAGE Information Systems Europe GmbH
Lifotronic - FA-160 Immunofluorescence Analyzer

Immunoassays

Lifotronic - FA-160 Immunofluorescence Analyzer

Lifotronic Technology Co., Ltd
Nova Biomedical – StatStrip Glucose/Ketone*

Blood Glucose

Nova Biomedical – StatStrip Glucose/Ketone*

Nova Biomedical Corporation
Sarstedt - COVID-19 virus diagnostics products

Saliva Collection

Sarstedt - COVID-19 virus diagnostics products

SARSTEDT AG & CO. KG
Sarstedt – CSF false-bottom tube

CSF and Alzheimer’s Disease Diagnostics

Sarstedt – CSF false-bottom tube

SARSTEDT AG & CO. KG
Subscribe to Newsletter